Nothing Special   »   [go: up one dir, main page]

CO6470817A2 - Cristales de solvato novedosos - Google Patents

Cristales de solvato novedosos

Info

Publication number
CO6470817A2
CO6470817A2 CO11161167A CO11161167A CO6470817A2 CO 6470817 A2 CO6470817 A2 CO 6470817A2 CO 11161167 A CO11161167 A CO 11161167A CO 11161167 A CO11161167 A CO 11161167A CO 6470817 A2 CO6470817 A2 CO 6470817A2
Authority
CO
Colombia
Prior art keywords
crystals
solvato
new
olmesartan
medoxomil
Prior art date
Application number
CO11161167A
Other languages
English (en)
Inventor
Hiroshi Kiyota
Hideaki Ishikawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6470817(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6470817A2 publication Critical patent/CO6470817A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cristales de solvato en acetona de tritilo-olmesartan-medoxomil útiles como intermediarios sintéticos del olmesartan-medoxomil. Un método para producir dichos cristales, el cual comprende un paso de precipitar los cristales de solvato en acetona de tritilo-olmesartan-medoxomil a partir de una solución de tritilo-olmesartan-medoxomil que contiene acetona.
CO11161167A 2009-04-28 2011-11-24 Cristales de solvato novedosos CO6470817A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009109160 2009-04-28

Publications (1)

Publication Number Publication Date
CO6470817A2 true CO6470817A2 (es) 2012-06-29

Family

ID=43032159

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11161167A CO6470817A2 (es) 2009-04-28 2011-11-24 Cristales de solvato novedosos

Country Status (19)

Country Link
US (2) US8859600B2 (es)
EP (1) EP2426127B1 (es)
JP (2) JP5697593B2 (es)
KR (1) KR20120006513A (es)
CN (1) CN102414201B (es)
AU (1) AU2010242635A1 (es)
BR (1) BRPI1013336B1 (es)
CA (1) CA2760031C (es)
CO (1) CO6470817A2 (es)
ES (1) ES2753874T3 (es)
IL (1) IL215965A0 (es)
MX (1) MX2011011540A (es)
MY (1) MY158090A (es)
NZ (1) NZ596326A (es)
RU (1) RU2563631C2 (es)
SG (2) SG10201501131SA (es)
TW (1) TWI464162B (es)
WO (1) WO2010126014A1 (es)
ZA (1) ZA201107813B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021224A2 (en) * 2009-08-19 2011-02-24 Msn Laboratories Limited Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
CN103214469B (zh) * 2013-04-29 2014-12-10 孙威 一种奥美沙坦酯化合物及其制备方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
CN110082449B (zh) * 2019-05-24 2020-05-19 珠海润都制药股份有限公司 一种奥美沙坦酯中三苯基氯甲烷的检测方法
CN113105439A (zh) * 2021-04-15 2021-07-13 迪嘉药业集团有限公司 一种小粒度奥美沙坦酯的结晶制备方法
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
JPH0753489A (ja) * 1993-06-11 1995-02-28 Sankyo Co Ltd ビフェニルカルボキサミド誘導体の製造法
JPH07121918A (ja) 1993-08-30 1995-05-12 Tdk Corp 光磁気記録媒体
JP3671266B2 (ja) 1996-03-21 2005-07-13 東洋化成工業株式会社 ５−置換テトラゾール類の製造方法
JP3521304B2 (ja) 1996-03-21 2004-04-19 東洋化成工業株式会社 １−（テトラゾリルビフェニルメチル）イミダゾール誘導体の製造方法
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JP2004217542A (ja) 2003-01-10 2004-08-05 Fuji Photo Film Co Ltd ４，５−ジアルコキシカルボニルイミダゾールの製造方法
WO2006029057A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Purification of olmesartan medoxomil
US20070054948A1 (en) 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
CN1976926A (zh) * 2004-09-02 2007-06-06 特瓦制药工业有限公司 奥美沙坦酯的制备
JP2006111586A (ja) 2004-10-15 2006-04-27 Nippon Petrochemicals Co Ltd 置換芳香族化合物の酸化方法
KR20090108739A (ko) 2005-01-03 2009-10-16 테바 파마슈티컬 인더스트리즈 리미티드 불순물의 양이 감소된 올메사탄 메독소밀
EA014026B1 (ru) 2005-07-29 2010-08-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения олмесартан медоксомила
SI22092A (sl) 2005-07-29 2007-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo olmesartan medoksomila
WO2007047838A2 (en) 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
CZ299902B6 (cs) 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
US8048904B2 (en) * 2006-06-19 2011-11-01 Matrix Laboratories Ltd. Process for the preparation of olmesartan medoxomil
ITMI20061848A1 (it) * 2006-09-27 2008-03-28 Dipharma Spa Procedimento per la preparazione di composti feniltetrazolici
US8076492B2 (en) 2006-10-09 2011-12-13 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
WO2009019303A2 (en) * 2007-08-08 2009-02-12 Lek Pharmaceuticals D.D. A process for the preparation or purification of olmesartan medoxomil
EP2036904A1 (en) * 2007-08-08 2009-03-18 LEK Pharmaceuticals D.D. A process for the preparation of olmesartan medoxomil
ES2540062T3 (es) 2008-06-09 2015-07-08 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto de 1-bifenilmetilimidazol
WO2010026255A1 (en) 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for preparing olmesartan medoxomil intermediate
US8933241B2 (en) * 2009-04-28 2015-01-13 Daiichi Sankyo Company, Limited Method for producing olmesartan medoxomil
WO2011014611A2 (en) 2009-07-30 2011-02-03 Dr. Reddy's Laboratories Ltd. Preparation of olmesartan medoxomil
US20130190506A1 (en) 2010-06-28 2013-07-25 Hetero Research Foundation Process for olmesartan medoxomil

Also Published As

Publication number Publication date
JP5697593B2 (ja) 2015-04-08
WO2010126014A1 (ja) 2010-11-04
US8859600B2 (en) 2014-10-14
US20160102079A1 (en) 2016-04-14
TWI464162B (zh) 2014-12-11
JP5944539B2 (ja) 2016-07-05
CN102414201A (zh) 2012-04-11
CA2760031C (en) 2015-03-10
CA2760031A1 (en) 2010-11-04
CN102414201B (zh) 2015-10-14
KR20120006513A (ko) 2012-01-18
BRPI1013336A2 (pt) 2016-03-29
US20120059172A1 (en) 2012-03-08
SG175296A1 (en) 2011-11-28
MY158090A (en) 2016-08-30
RU2563631C2 (ru) 2015-09-20
EP2426127A1 (en) 2012-03-07
ZA201107813B (en) 2012-07-25
JPWO2010126014A1 (ja) 2012-11-01
MX2011011540A (es) 2012-04-30
SG10201501131SA (en) 2015-04-29
AU2010242635A1 (en) 2011-12-01
TW201043616A (en) 2010-12-16
AU2010242635A2 (en) 2014-08-07
ES2753874T3 (es) 2020-04-14
BRPI1013336B1 (pt) 2020-02-04
JP2015071647A (ja) 2015-04-16
NZ596326A (en) 2014-02-28
RU2011148101A (ru) 2013-06-10
IL215965A0 (en) 2012-01-31
EP2426127B1 (en) 2019-09-04
EP2426127A4 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
UY34095A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
EA201291156A1 (ru) Композиции с наноносителями с неприсоединенным адъювантом
BR112014019909A8 (pt) Processo para produção de compostos úteis como antagonistas do receptor de orexina-2
GT201500042A (es) Producción de dienos volátiles por deshidratación enzimática de alquenoles ligeros
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
BR112015010557A2 (pt) método para a produção de fenol a partir de fontes renováveis por meio de fermentação.
CO6470817A2 (es) Cristales de solvato novedosos
CL2014001960A1 (es) Metodo para producir una composición que contiene galacto-oligosacáridos.
EA201300513A1 (ru) Волокна для контролируемого разложения
BR112013001109A2 (pt) composição que contém galacto-oligossacarídeos e método para produzi-la
DOP2015000187A (es) Proceso de fabricación de vortioxetina
BR112013016241A2 (pt) composto, e, método para fabricar um composto
GT201300256A (es) Procesos para la elaboración de depsipéptidos macrocíclicos y nuevos intermediarios
ITRM20110520A1 (it) Metodo per la realizzazione di filati di fibre di carbonio di riciclo.
BR122021023230B8 (pt) Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado
BR112012003958A2 (pt) método para produzir um l-aminoácido.
ECSP12011603A (es) Derivados de pirazinooxazepina
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
CO6410291A2 (es) 3-amino-2-mercaptoquinolina sustituidacomo modulador de kcnq2/3
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
BR112012000258A2 (pt) processo para preparar uma alquenona.
BR112012020855A2 (pt) Método para produzir um conjugado de biomolécula
BRPI1007069A2 (pt) Método para produzir um l-aminoácido.

Legal Events

Date Code Title Description
FC Application refused